Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Jill Roberts Center for Inflammatory Bowel Disease
Explore this Website
Home
About Us
Toggle About Us menu options
Clinical Staff
Research Staff
Contact Us
Newsworthy
Toggle Newsworthy menu options
News and Announcements
Patient Care
Toggle Patient Care menu options
Clinical Services
FAQs
For Your Visit
COVID-19 Information
Nutrition Science
Toggle Nutrition Science menu options
Nutrition FAQs
Food Intolerances
News in IBD Nutrition
Research and Clinical Trials
Toggle Research and Clinical Trials menu options
Clinical Trials
Publications
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
Newsworthy
Patient Care
Nutrition Science
Research and Clinical Trials
Home
Publications
Publications
Clinical Trials
Publications
Publications
Found 102 results
Author
Title
Type
[
Year
]
Filters:
First Letter Of Last Name
is
C
[Clear All Filters]
2018
Dulai PS
,
Boland BS
,
Singh S
,
Chaudrey K
,
Koliani-Pace JL
,
Kochhar G
,
Parikh MP
,
Shmidt E
,
Hartke J
,
Chilukuri P
et al.
. 2018.
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.
.
Gastroenterology. 155(3):687-695.e10.
Dulai PS
,
Boland BS
,
Singh S
,
Chaudrey K
,
Koliani-Pace JL
,
Kochhar G
,
Parikh MP
,
Shmidt E
,
Hartke J
,
Chilukuri P
et al.
. 2018.
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.
.
Gastroenterology. 155(3):687-695.e10.
Dulai PS
,
Boland BS
,
Singh S
,
Chaudrey K
,
Koliani-Pace JL
,
Kochhar G
,
Parikh MP
,
Shmidt E
,
Hartke J
,
Chilukuri P
et al.
. 2018.
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.
.
Gastroenterology. 155(3):687-695.e10.
Dulai PS
,
Boland BS
,
Singh S
,
Chaudrey K
,
Koliani-Pace JL
,
Kochhar G
,
Parikh MP
,
Shmidt E
,
Hartke J
,
Chilukuri P
et al.
. 2018.
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.
.
Gastroenterology. 155(3):687-695.e10.
Dulai PS
,
Boland BS
,
Singh S
,
Chaudrey K
,
Koliani-Pace JL
,
Kochhar G
,
Parikh MP
,
Shmidt E
,
Hartke J
,
Chilukuri P
et al.
. 2018.
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.
.
Gastroenterology. 155(3):687-695.e10.
Dogan B
,
Belcher-Timme HFacey
,
Dogan EI
,
Jiang Z-D
,
Dupont HL
,
Snyder N
,
Yang S
,
Chandler B
,
Scherl EJ
,
Simpson KW
. 2018.
Evaluation of Escherichia coli pathotypes associated with irritable bowel syndrome.
.
FEMS Microbiol Lett. 365(22)
Cohen-Mekelburg S
,
Rosenblatt R
,
Gold S
,
Burakoff R
,
Waljee AK
,
Saini S
,
Schackman BR
,
Scherl E
,
Crawford C
. 2018.
The Impact of Opioid Epidemic Trends on Hospitalised Inflammatory Bowel Disease Patients.
.
J Crohns Colitis. 12(9):1030-1035.
Cohen-Mekelburg S
,
Rosenblatt R
,
Gold S
,
Burakoff R
,
Waljee AK
,
Saini S
,
Schackman BR
,
Scherl E
,
Crawford C
. 2018.
The Impact of Opioid Epidemic Trends on Hospitalised Inflammatory Bowel Disease Patients.
.
J Crohns Colitis. 12(9):1030-1035.
Castellanos JG
,
Woo V
,
Viladomiu M
,
Putzel G
,
Lima S
,
Diehl GE
,
Marderstein AR
,
Gandara J
,
Perez AR
,
Withers DR
et al.
. 2018.
Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis.
.
Immunity. 49(6):1077-1089.e5.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
Shmidt E
,
Kochhar G
,
Hartke J
,
Chilukuri P
,
Meserve J
,
Chaudrey K
,
Koliani-Pace JL
,
Hirten R
,
Faleck D
,
Barocas M
et al.
. 2018.
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 24(11):2461-2467.
Battat R
,
Duijvestein M
,
Casteele NVande
,
Singh S
,
Dulai PS
,
Valasek MA
,
Mimms L
,
McFarland J
,
Hester KD
,
Renshaw M
et al.
. 2018.
Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease.
.
Clin Gastroenterol Hepatol.
Cohen-Mekelburg S
,
Tafesh Z
,
Coburn E
,
Weg R
,
Malik N
,
Webb C
,
Hammad H
,
Scherl E
,
Bosworth BP
. 2018.
Testing and Treating Small Intestinal Bacterial Overgrowth Reduces Symptoms in Patients with Inflammatory Bowel Disease.
.
Dig Dis Sci. 63(9):2439-2444.
Cohen-Mekelburg S
,
Tafesh Z
,
Coburn E
,
Weg R
,
Malik N
,
Webb C
,
Hammad H
,
Scherl E
,
Bosworth BP
. 2018.
Testing and Treating Small Intestinal Bacterial Overgrowth Reduces Symptoms in Patients with Inflammatory Bowel Disease.
.
Dig Dis Sci. 63(9):2439-2444.
Narula N
,
Peerani F
,
Meserve J
,
Kochhar G
,
Chaudrey K
,
Hartke J
,
Chilukuri P
,
Koliani-Pace J
,
Winters A
,
Katta L
et al.
. 2018.
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
.
Am J Gastroenterol. 113(9):1345.
Narula N
,
Peerani F
,
Meserve J
,
Kochhar G
,
Chaudrey K
,
Hartke J
,
Chilukuri P
,
Koliani-Pace J
,
Winters A
,
Katta L
et al.
. 2018.
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
.
Am J Gastroenterol. 113(9):1345.
Narula N
,
Peerani F
,
Meserve J
,
Kochhar G
,
Chaudrey K
,
Hartke J
,
Chilukuri P
,
Koliani-Pace J
,
Winters A
,
Katta L
et al.
. 2018.
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
.
Am J Gastroenterol. 113(9):1345.
Narula N
,
Peerani F
,
Meserve J
,
Kochhar G
,
Chaudrey K
,
Hartke J
,
Chilukuri P
,
Koliani-Pace J
,
Winters A
,
Katta L
et al.
. 2018.
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
.
Am J Gastroenterol. 113(9):1345.
2017
Battat R
,
Kopylov U
,
Bessissow T
,
Bitton A
,
Cohen A
,
Jain A
,
Martel M
,
Seidman E
,
Afif W
. 2017.
Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
.
Clin Gastroenterol Hepatol. 15(9):1427-1434.e2.
Viladomiu M
,
Kivolowitz C
,
Abdulhamid A
,
Dogan B
,
Victorio D
,
Castellanos JG
,
Woo V
,
Teng F
,
Tran NL
,
Sczesnak A
et al.
. 2017.
IgA-coated enriched in Crohn's disease spondyloarthritis promote T17-dependent inflammation.
.
Sci Transl Med. 9(376)
Viladomiu M
,
Kivolowitz C
,
Abdulhamid A
,
Dogan B
,
Victorio D
,
Castellanos JG
,
Woo V
,
Teng F
,
Tran NL
,
Sczesnak A
et al.
. 2017.
IgA-coated enriched in Crohn's disease spondyloarthritis promote T17-dependent inflammation.
.
Sci Transl Med. 9(376)
Jacob V
,
Crawford C
,
Cohen-Mekelburg S
,
Viladomiu M
,
Putzel GG
,
Schneider Y
,
Chabouni F
,
OʼNeil S
,
Bosworth B
,
Woo V
et al.
. 2017.
Single Delivery of High-Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative Colitis.
.
Inflamm Bowel Dis. 23(6):903-911.
« first
‹ previous
1
2
3
(current)
4
5
next ›
last »